Toremifene

IARC Monographs on the Evaluation of Carcinogenic Risks to Humans

Volumn 66, Issue , 1996, Pages 367-387

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; CARCINOGEN; TOREMIFENE;

ANIMAL; CARCINOGEN TESTING; HUMAN; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; CARCINOGENICITY TESTS; CARCINOGENS; ESTROGEN ANTAGONISTS; HUMANS; TOREMIFENE;

EID: 0030325485     PISSN: 02509555     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Review

References (66)

1. Ahotupa, M., Hirsimäki, P., Pärssinen, R. & Mäntylä, E. (1994) Alterations of drug metabolizing and antioxidant enzyme activities during tamoxifen-induced hepatocarcinogenesis in the rat. Carcinogenesis, 15, 863-868
2. Anon. (1995a) European OK for Fareston. Scrip, 2073, 22
3. Anon. (1995b) Scherling-Plough granted U.S. marketing rights for Fareston. Drug News Perspectives, April 18
4. Anttila, M., Valavaara, R., Kivinen, S. & Mäenpää, J. (1990) Pharmacokinetics of toremifene. J. Steroid Biochem., 36, 249-252
5. Anttila, M., Laakso, S., Nyländen, P. & Sotaniemi, E.A. (1995) Pharmacokinetics of the novel antiestrogenic agent toremifene in subjects with altered liver and kidney function. Clin. Pharmacol. Ther., 57, 628-635
6. Berthou, F. & Dréano, Y. (1993) High-performance liquid chromatographic analysis of tamoxifen, toremifene and their major human metabolites. J. Chromatogr., 616, 117-127
7. Berthou, F., Dréano, Y., Belloc, C., Kangas, L., Gautier, J.-C. & Beaune, P. (1994) Involvement of cytochrome P450 3A enzyme family in the major metabolic pathways of toremifene in human liver microsomes. Biochem. Pharmacol., 47, 1883-1895
8. Bishop, J., Murray, R., Webster, L., Pitt, P., Stokes, K., Fennessy, A., Olver, I. & Leber, G. (1992) Phase I clinical and pharmacokinetics study of high-dose toremifene in post-menopausal patients with advanced breast cancer. Cancer Chemother. Pharmacol., 30, 174-178
9. Budavari, S., ed. (1995) The Merck Index, 12th Ed., Rahway, NJ, Merck & Co.
10. Davies, A.M., Martin, E.A., Jones, R.M., Lim, C.K., Smith, L.L. & White, I.N.H. (1995) Peroxidase activation of tamoxifen and toremifene resulting in DNA damage and covalently bound protein adducts. Carcinogenesis, 16, 539-545
11. Dragan , Y.P., Vaughan, J., Jordan, V.C. & Pitot, H.C. (1995) Comparison of the effects of tamoxifen and toremifene on liver and kidney tumor promotion in female rats. Carcinogenesis, 16, 2733-2741
12. European Commission (1996) Fareston Containing Toremifene, Directorate General III, Brussels
13. 8-cholesterol conversion to lathosterol in women with breast cancer. J. clin. Oncol., 13, 2900-2905
14. Hamm, J.T., Tormey, D.C., Kohler, P.C., Haller, D., Green, M. & Shemano, I. (1991) Phase I study of toremifene in patients with advanced cancer. J. clin. Oncol., 9, 2036-2041
15. Hard, G.C., Iatropoulos, M.J., Jordan, K., Radi, L., Kaltenberg, O.P., Imondi, A.R. & Williams, G.M. (1993) Major difference in the hepatocarcinogenicity and DNA adduct forming ability between toremifene and tamoxifen in female Crl:CD(BR) rats. Cancer Res., 53, 4534-4541
16. Hasan, S.A., Wiebe, V.J., Cadman, K.S. & DeGregorio, M.W. (1990) Quantitative analysis of toremifene metabolites in biological specimens using high-performance liquid chromatography. Analyt. Lett., 23, 327-334
17. Hayes, D.F., Van Zyl, J.A., Hacking, A., Goedhals, L., Bezwoda, W.R., Mailliard, J.A., Jones, S.E., Vogel, C.L., Berris, R.F., Shemano, I. & Schoenfelder, J. (1995) Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer. J. clin. Oncol., 13, 2556-2566
18. Hemminki, K., Widlak, P. & Hou, S.-M. (1995) DNA adducts caused by tamoxifen and toremifene in human microsomal system and lymphocytes in vitro. Carcinogenesis, 16, 1661-1664
19. Hietanen, T., Baltina, D., Johansson, R., Numminen, S., Hakala, T., Helle, L. & Valavaara, R. (1990) High dose toremifene (240 mg daily) is effective as first line hormonal treatment in advanced breast cancer. An ongoing phase II multicenter Finnish-Latvian cooperative study. Breast Cancer Res. Treat., 16 (Suppl.), S37-S40
20. Hirsimäki, Y., Beltrame, D., McAnulty, P., Tesh, J. & Wong, L. (1990) Preliminary investigations of the reproductive consequences of toremifene citrate treatment (Abstract no. 890). Toxicologist, 10, 223
21. Hirsimäki, P., Hirsimäki, Y., Nieminen, L. & Payne, B.J. (1993) Tamoxifen induces hepatocellular carcinoma in rat liver: a 1-year study with two antiestrogens. Arch. Toxicol., 67, 49-54
22. Holleran, W.M., Gharbo, S.A. & DeGregorio, M.W. (1987) Quantitation of toremifene and its major metabolites in human plasma by high-performance liquid chromatography following fluorescent activation. Analyt. Lett., 20, 871-879
23. Horvath, G., Stendahl, U., Kalling, M., Fernö, M., Himmelmann, A. & Hajba, A. (1990) Antiestrogenic treatment of advanced and recurrent carcinoma corporis uteri - A phase II study of toremifene. Anticancer Res., 10, 323-326
24. Huovinen, R. & Collan, Y. (1994) Cell loss in dimethylbenz(a)anthracene-induced rat mammary carcinoma treated with toremifene and ovariectomy. Tumor Biol., 15, 345-353
25. Jönsson, P.-E., Malmberg, M., Bergljung, L., Ingvar, C., Ericsson, M., Ryden, S., Nilsson, I., & Johansson Terje, I. (1991) Phase II study of high dose toremifene in advanced breast cancer progressing during tamoxifen treatment. Anticancer Res., 11, 873-875
26. Kallio, S., Kangas, L., Blanco, G., Johansson, R., Karjalainen, A., Perilä, M., Pippo, I., Sundquist, H., Södervall, M. & Toivola, R. (1986) A new triphenylethylene compound, Fc-1157a. I. Hormonal effects. Cancer Chemother. Pharmacol., 17, 103-108
27. Kangas, L. (1990) Biochemical and pharmacological effects of toremifene metabolites. Cancer Chemother. Pharmacol., 27, 8-12
28. Kangas, L. (1992) Agonistic and antagonistic effects of antioestrogens in different target organs. Acta oncol., 31, 143-146
29. Kangas, L., Nieminen, A.-L., Blanco, G., Grönroos, M., Kallio, S., Karjalainen, A., Perilä, M., Södervall, M. & Toivola, R. (1986) A new triphenylethylene compound, Fc-1157a. II. Antitumor effects. Cancer Chemother. Pharmacol., 17, 109-113
30. Karlsson, S., Hirsimäki, Y., Mäntylä, E., Nieminen, L., Kangas, L., Hirsimäki, P., Perry, C.J., Mulhern, M., Millar, P., Handa, J. & Williams, G.M. (1996) A two-year dietary carcinogenicity study of the antiestrogen toremifene in Sprague-Dawley rats. Drug chem. Toxicol. (in press)
31. Kendall, M.E. & Rose, D.P. (1992) The effects of diethylstilbestrol, tamoxifen, and toremifene on estrogen-inducible hepatic proteins and estrogen receptor proteins in female rats. Toxicol. appl. Pharmacol., 144, 127-131
32. Kivinen, S. & Mäenpää, J. (1990) Effect of toremifene on clinical chemistry, hematology and hormone levels at different doses in healthy postmenopausal volunteers: phase I study. J. Steroid Biochem., 36, 217-220
33. Kleeberg, U.R., Engel, E., Bröcker, E.B., Avril, F., Israels, P., Weiss, J., Kangas, L., van Glabbeke, M. & Lentz, M. A. (1993) Effect of toremifene in patients with metastatic melanoma: a phase II study of the EORTC melanoma cooperative group. Melanoma Res., 3, 123-126
34. Kohler, P.C., Hamm, J.T., Wiebe, V.J., DeGregorio, M.W., Shemano, I. & Tormey, D.C. (1990) Phase I study of the tolerance and pharmacokinetics of toremifene in patients with cancer. Breast Cancer Res. Treatment, 16 (Suppl.), S19-S26
35. Lim, C.K., Yuan, Z.-X., Ying, K.-C. & Smith, L.L. (1994) High-performance liquid chromatography of toremifene and metabolites. J. liq. Chromatogr., 17, 1773-1783
36. Mäenpää, J.U., Sipilä, P.E.-H. & Hajba, A. (1992a) Toremifene for recurrent and advanced endometrial carcinoma (Letter to the Editor). Eur. J. Cancer, 28A, 1768
37. Mäenpää, J.U., Sipilä, P.E.-H., Kangas, L., Karnani, P. & Grönroos, M. (1992b) Chemosensitizing effect of an antiestrogen, toremifene, on ovarian cancer. Gynecol. Oncol., 46, 292-297
38. Mäntylä, E.T.E., Karlsson, S.H. & Nieminen, L.S. (1996) Induction of endometrial cancer by tamoxifen in the rat. In: Li, J.J., Li, S.A., Gustafsson, J.-Å., Nandi, S. & Sekely, L.I., eds, Hormonal Carcinogenesis II, Proceedings of the Second International Symposium, New York, Springer-Verlag
39. Montandon, F. & Williams, G.M. (1994) Comparison of DNA reactivity of the polyphenylethylene hormonal agents diethylstilbestrol, tamoxifen and toremifene in rat and hamster liver. Arch. Toxicol., 68, 272-275
40. Moon, R.C., Steele, V.E., Kelloff, G.J., Thomas, C.F., Detrisac, C.J., Mehta, R.G. & Lubet, R.A. (1994) Chemoprevention of MNU-induced mammary tumorigenesis by hormone response modifiers: toremifene, RU 16117, tamoxifen, aminoglutethimide and progesterone. Anticancer Res., 14, 889-893
41. Nomura, Y., Tominaga, T., Abe, O., Izuo, M. & Ogana, N. (1993) Clinical evaluation of NK 622 (toremifene citrate) in advanced or recurrent breast cancer - A comparative study by a double blind method with tamoxifen. Jpn. J. Cancer Chemother., 20, 247-258 (in Japanese)
42. Orion (1996) Toremifene, Orion-Farmos, Turku, Finland
43. Potter, G.A., McCague, R. & Jarman, M. (1994) A mechanistic hypothesis for DNA adduct formation by tamoxifen following hepatic oxidative metabolism. Carcinogenesis, 15, 439-442
44. Pyrhönen, S.O. (1990) Phase III studies of toremifene in metastatic breast cancer. Breast Cancer Res. Treat., 16 (Suppl.), S41-S46
45. Pyrhönen, S.O., Valavaara, R., Heikkinen, M., Rissanen, P., Blanco, G., Nordman, E., Holsti, L.R. & Hajba, A. (1990) Treatment of advanced breast cancer with 20 mg toremifene, a phase II study. Preliminary communication. J. Steroid Biochem., 36, 227-228
46. Pyrhönen, S.O., Valavaara, R., Vuorinen, J. ̈ Hajba, A. (1994) High dose toremifene in advanced breast cancer resistant to or relapsed during tamoxifen treatment. Breast Cancer Res. Treat., 29, 223-228
47. Robinson, S.P., Mauel, D.A. & Jordan, V.C. (1988) Antitumor actions of toremifene in the 7,12-dimethylbenzanthracene (DMBA)-induced rat mammary tumor model. Eur. J. Cancer clin. Oncol., 24, 1817-1821
48. di Salle, E., Zaccheo, T. & Ornati, G. (1990) Antiestrogenic and antitumor properties of the new triphenylethylene derivative toremifene in the rat. J. Steroid Biochem., 36, 203-206
49. Simberg, N.H., Murai, J.T. & Siiteri, P.K. (1990) In vitro and in vivo binding of toremifene and its metabolites in rat uterus. J. Steroid Biochem., 36, 197-202
50. Sipilä, H., Kangas, L., Vuorilehto, L., Kalapudas, A., Eloranta, M., Södervall, M., Toivola, R. & Anttila, M. (1990) Metabolism of toremifene in the rat J. Steroid Biochem., 36, 211-215
51. Stenbygaard, L.E., Herrstedt, J., Thomsen, J.F., Svendsen, K.R., Engelholm, S.A. & Dombernowsky, P. (1993) Toremifene and tamoxifen in advanced breast cancer - a double-blind cross-over trial. Breast Cancer Res. Treat., 25, 57-63
52. Styles, J.A., Davies, A., Lim, C.K., De Matteis, F., Stanley, L.A., White, I.N.H., Yuan, Z.-X. & Smith, L.L. (1994) Genotoxicity of tamoxifen, tamoxifen epoxide and toremifene in human lymphoblastoid cells containing human cytochrome P450s. Carcinogenesis, 15, 5-9
53. Számel, I., Hindy, I., Vincze, B., Eckhardt, S., Kangas, L. & Hajba, A. (1994) Influence of toremifene on the endocrine regulation in breast cancer patients. Eur. J. Cancer, 30A, 154-158
54. Tomás, E., Kauppila, A., Blanco, G., Apaja-Sarkkinen, M. & Laatikainen, T. (1995) Comparison between the effects of tamoxifen and toremifene on the uterus in postmenopausal breast cancer patients. Gynecol. Oncol., 59, 261-266
55. Valavaara, R. (1990) Phase II trials with toremifene in advanced breast cancer: a review. Breast Cancer Res. Treat., 16(Suppl.), S31-S35
56. Valavaara, R. & Pyrhönen, S.O. (1989) Low-dose toremifene in the treatment of estrogen-receptor-positive advanced breast cancer in postmenopausal women. Current ther. Res., 46, 966-973
57. Valavaara, R., Pyrhönen, S.O., Heikkinen, M., Rissanen, P., Blanco, G., Thölix, E., Nordman, E., Taskinen, P., Holsti, L. & Hajba, A. (1988) Toremifene, a new anti-estrogenic compound for treatment of advanced breast cancer. Phase II study. Eur. J. Cancer clin. Oncol., 24, 785-790
58. Valavaara, R., Tuominen, J. & Toivanen, A. (1990) The immunological status of breast cancer patients during treatment with a new antiestrogen, toremifene. Cancer Immunol. Immunother., 31, 381-386
59. Vogel, C.L., Shemano, I., Schoenfelder, J., Gams, R.A. & Green, M.R. (1993) Multicenter phase II efficacy trial of toremifene in tamoxifen-refractory patients with advanced breast cancer. J. clin. Oncol., 11, 345-350
60. Watanabe, N., Irie, T., Koyama, M. & Tominaga, T. (1989) Liquid chromatographic-atmospheric pressure ionization mass spectrometric analysis of toremifene metabolites in human urine. J. Chromatogr., 497, 169-180
61. Webster, L.K., Crinis, N.A., Stokes, K.H. & Bishop, J.F. (1991) High-performance liquid chromatographic method for the determination of toremifene and its major human metabolites. J. Chromatogr., 565, 482-487
62. Webster, L.K., Ellis, A.G. & Bishop, J.F. (1993) Effect of toremifene on antipyrine elimination in the isolated perfused rat liver. Cancer Chemother. Pharmacol., 31, 319-323
63. White, I.N.H., De Matteis, F., Davies, A., Smith, L.L., Crofton-Sleigh, C., Venitt, S., Hewer, A. & Phillips, D.H. (1992) Genotoxic potential of tamoxifen and analogues in female Fischer F344/n rats, DBA/2 and C57B1/6 mice and in human MCL-5 cells. Carcinogenesis, 13, 2197-2203
64. White, I.N.H., Davies, A., Smith, L.L., Dawson, S. & De Matteis, F. (1993) Induction of CYP2B1 and 3A1, and associated monooxygenase activities by tamoxifen and certain analogues in the livers of female rats and mice. Biochem. Pharmacol., 45, 21-30
65. Wiebe, V.J., Benz, C.C., Shemano, I., Cadman, T.B. & DeGregorio, M.W. (1990) Pharmacokinetics of toremifene and its metabolites in patients with advanced breast cancer. Cancer Chemother. Pharmacol., 25, 247-251
66. Wood, J.D., Glaister, J.R., Goodyer, M.J., Yamashita, T. & Nakamori, K. (1992) Week oral toxicity study of toremifene citrate (NK622) in female monkeys. Pharmacometrics (Japan), 44(4), 375-387